MAPK Cancer Research Results

MAPK, mitogen-activated protein kinase: Click to Expand ⟱
Source: CGL-CS
Type:
Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.


IBD, Inflammatory Bowel Disease: Click to Expand ⟱
Inflammatory Bowel Disease

The main pathways involved in IBD include intestinal barrier dysfunction, mucus barrier impairment, dysbiosis-driven innate immune activation, and persistent cytokine-mediated inflammation. Key barrier components such as ZO-1, occludin, claudins, and MUC2 are commonly disrupted, increasing epithelial permeability and microbial translocation. This promotes activation of inflammatory hubs including TNF-α, NF-κB, IL-1β, IL-6/STAT3, and IL-23/Th17, while JAK/STAT signaling integrates multiple cytokine inputs that sustain chronic mucosal injury. Together, these pathways drive epithelial damage, immune dysregulation, and failure of mucosal healing in ulcerative colitis and Crohn’s disease

Rank Pathway / Axis Representative Targets / Markers Typical Direction in IBD Main Relevance
1 Intestinal Barrier Integrity / Tight Junctions ZO-1 (TJP1), Occludin (OCLN), Claudins (especially CLDN2, CLDN1) ZO-1 ↓, OCLN ↓, barrier loosened; CLDN2 often ↑ Core barrier failure increases intestinal permeability, microbial entry, and chronic inflammation
2 Mucus Barrier / Goblet Cell Axis MUC2, goblet cells, antimicrobial peptides MUC2 and goblet protection often impaired Weak mucus defense exposes the epithelium to luminal bacteria and antigens
3 TNF-α Inflammatory Axis TNF-α, TNFR1, TNFR2 Major inflammatory driver and validated therapeutic target in IBD
4 NF-κB Signaling NF-κB, IKK, IκB, COX-2, iNOS Central transcriptional hub for cytokines, chemokines, and inflammatory amplification
5 IL-23 / Th17 Axis IL-23, IL-23R, IL-17A, IL-22, RORγt ↑ / dysregulated Important bridge between innate and adaptive immune inflammation
6 JAK / STAT Signaling JAK1, JAK2, TYK2, STAT3 ↑ / activated Integrates multiple cytokine signals that sustain mucosal inflammation
7 IL-6 / STAT3 Axis IL-6, IL-6R, gp130, STAT3 Supports inflammatory persistence, immune-cell survival, and epithelial injury signaling
8 IL-1β / Inflammasome Axis IL-1β, NLRP3, ASC, caspase-1 Promotes innate inflammation, cytokine escalation, and epithelial damage
9 Microbiota / Dysbiosis / PRR Signaling Dysbiosis, TLRs, MyD88, LPS-related signaling Dysregulated / activated Links altered microbiota to barrier loss and immune activation
10 Oxidative Stress / Redox Imbalance ROS, lipid peroxidation, MPO, antioxidant defenses ↑ oxidative stress Contributes to epithelial injury, inflammatory signaling, and impaired healing
11 Leukocyte Trafficking / Adhesion Integrins, MAdCAM-1, ICAM-1, VCAM-1, chemokines Drives immune-cell recruitment into inflamed intestinal tissue
12 Epithelial Apoptosis / Restitution / Mucosal Healing Caspases, repair pathways, epithelial proliferation and restitution markers Injury ↑, healing impaired Determines whether mucosal damage resolves or progresses to chronic disease
Rank Natural Product Best Fit in IBD Evidence Level Main Rationale Notes
1 Curcumin Mainly Ulcerative Colitis (UC) Best human evidence Strongest overall adjunctive clinical support among common natural products for active UC Anti-inflammatory; NF-κB / cytokines / oxidative stress; mucosal support
2 Indigo naturalis (Qing Dai) Mainly UC Strong efficacy, safety-limited Good human efficacy signals, but safety concerns lower practical rank Anti-colitic; immune/inflammatory modulation; use caution flag for safety
3 Boswellia serrata UC / colitis Older smaller human trials Suggestive remission data and anti-inflammatory relevance, but evidence base is limited 5-LOX / leukotrienes / inflammation / mucosal protection
4 Aloe vera gel Mild-to-moderate UC Small human trial signal Some human improvement signal, though not as strong as curcumin or indigo naturalis Mucosal soothing / anti-inflammatory / healing support
5 Andrographis paniculata / andrographolide Mostly UC Mixed human, stronger preclinical Mechanistically promising, but human benefit is less consistent NF-κB / cytokines / barrier and anti-inflammatory support
6 Carvacrol Experimental colitis / dysbiosis / barrier dysfunction Preclinical Promising anti-colitis terpene with anti-inflammatory, antioxidant, and microbiota-related effects Dysbiosis / intestinal barrier integrity / NF-κB / oxidative stress
7 Thymol Experimental colitis / barrier dysfunction Preclinical Promising anti-colitis terpene with cytokine suppression and NF-κB-related effects Dysbiosis / intestinal barrier integrity / NF-κB / COX-2 / oxidative stress
8 Carvacrol + Thymol Experimental colitis, dysbiosis, bile-acid modulation Preclinical, mechanistically strong Combination may be especially relevant due to microbiota and bile-acid pathway effects in DSS colitis Bifidobacterium / secondary bile acids / barrier support / anti-colitic signaling
9 Peppermint oil Supportive / experimental colitis / GI symptom relief Mainly preclinical for IBD; stronger IBS evidence Menthol-rich oil with anti-inflammatory, antispasmodic, and possible barrier-supportive effects, but limited direct human IBD evidence Menthol / TRP modulation / cytokines / oxidative stress / GI symptom support


Scientific Papers found: Click to Expand⟱
5577- B-Gluc,    Lentinan progress in inflammatory diseases and tumor diseases
- Review, Var, NA - Review, IBD, NA
AntiTum↑, GutMicro↑, *Inflam↓, *TNF-α↓, *NF-kB↓, ChemoSen↑, OS↑, Imm↑, IL6↓, ERK↓, MAPK↓, *antiOx↑, eff↑,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
5943- Cela,    Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases
- Review, Arthritis, NA - Review, IBD, NA - Review, AD, NA - Review, Park, NA
*other↝, *other↝, *CRP↓, *eff↝, *other↑, *CXCR4↓, *IL1β↓, *IL6↓, *IL17↓, *IL18↓, *TNF-α↓, *MMP9↓, *PGE2↓, *COX1↓, *COX2↓, *PI3K↓, *Akt↓, *other↑, TumCCA↑, Apoptosis↑, ROS↑, JNK↑, TumAuto↑, Hif1a↓, BNIP3↝, HSP90↓, Fas↑, FasL↑, ETC↓, VEGF↓, angioG↓, RadioS↑, *neuroP↑, *HSP70/HSPA5↑, *ROS↓, *MMP↑, *Cyt‑c↓, *Casp3↓, *Casp9↓, *MAPK↓, *Dose⇅, *HSPs↑, BioAv↓, Dose↝,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↑, 2,  

Mitochondria & Bioenergetics

CDC25↓, 2,   ETC↓, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis

AMPK↑, 1,  

Cell Death

Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↓, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Fas↑, 2,   FasL↑, 2,   IAP1↓, 1,   JNK↑, 1,   MAPK↓, 2,   MDM2↓, 1,   survivin↓, 1,  

Transcription & Epigenetics

other↓, 1,  

Protein Folding & ER Stress

HSP90↓, 1,  

Autophagy & Lysosomes

BNIP3↝, 1,   LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair

ATM↑, 1,   P53↑, 1,  

Cell Cycle & Senescence

CycB/CCNB1↓, 1,   RB1↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State

EMT↑, 1,   ERK↓, 2,   mTOR↓, 1,   RAS↓, 1,  

Migration

FAK↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   Rho↓, 1,   ROCK1↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature

angioG↓, 2,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling

CD4+↓, 1,   COX2↓, 2,   IL1↓, 1,   IL6↓, 2,   Imm↑, 1,   Inflam↓, 1,   MCP1↓, 1,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   ChemoSen↑, 2,   Dose↝, 1,   eff↑, 3,   RadioS↑, 1,  

Clinical Biomarkers

GutMicro↑, 1,   IL6↓, 2,  

Functional Outcomes

AntiCan↑, 1,   AntiTum↑, 2,   OS↑, 1,   RenoP↑, 1,  
Total Targets: 72

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   ROS↓, 2,  

Mitochondria & Bioenergetics

MMP↑, 1,  

Cell Death

Akt↓, 1,   Casp3↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics

other↑, 2,   other↝, 2,  

Protein Folding & ER Stress

HSP70/HSPA5↑, 1,   HSPs↑, 1,  

Proliferation, Differentiation & Cell State

PI3K↓, 1,  

Migration

MMP9↓, 1,  

Immune & Inflammatory Signaling

COX1↓, 1,   COX2↓, 1,   CRP↓, 1,   CXCR4↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance

Dose⇅, 1,   eff↝, 1,  

Clinical Biomarkers

CRP↓, 1,   IL6↓, 1,  

Functional Outcomes

neuroP↑, 1,  
Total Targets: 33

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase
1 beta-glucans
1 Berberine
1 Celastrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:58  Cells:%  prod#:%  Target#:181  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page